ReviewMolecular biotechnology2005
Overview of vaccines and vaccination.
Review in Molecular biotechnology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Immunogenicity and safety of routine vaccines in children and adolescents with rheumatic diseases on immunosuppressive treatment - a systematic review.European journal of pediatrics · 2022Pooled it
- Tetravalent SARS-CoV-2 S1 Subunit Protein Vaccination Elicits Robust Humoral and Cellular Immune Responses in SIV-Infected Rhesus Macaque Controllers.bioRxiv : the preprint server for biology · 2023Article
- Trivalent SARS-CoV-2 S1 Subunit Protein Vaccination Induces Broad Humoral Responses in BALB/c Mice.Vaccines · 2023Article
- Higher sensitivity monitoring of reactions to COVID-19 vaccination using smartwatches.NPJ digital medicine · 2022Article
- Update on COVID-19 and Effectiveness of a Vaccination Campaign in a Global Context.International journal of environmental research and public health · 2022Review
- Vaccines platforms and COVID-19: what you need to know.Tropical diseases, travel medicine and vaccines · 2022Review
- Adenovirus-vectored SARS-CoV-2 vaccine expressing S1-N fusion protein.Antibody therapeutics · 2022Article
- Review
- Vaccination against SARS-CoV-2: a human enhancement story.Translational medicine communications · 2021Review
- A Heterologous Viral Protein Scaffold for Chimeric Antigen Design: An Example PCV2 Virus Vaccine Candidate.Viruses · 2020Article
- Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines.Frontiers in immunology · 2020Review
- Exploring the impact of inoculum dose on host immunity and morbidity to inform model-based vaccine design.PLoS computational biology · 2018Article
- Postgenomic Approaches and Bioinformatics Tools to Advance the Development of Vaccines against Bacteria of theVaccines · 2018Review
- Review
- Recombinant vaccines and the development of new vaccine strategies.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2012Article
- DNA vaccines for targeting bacterial infections.Expert review of vaccines · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Of the 80-plus known infectious agents pathogenic for humans, there are now more than 30 vaccines against 26 mainly viral and bacterial infections and these greatly minimize subsequent disease and prevent death after exposure to those agents. This article describes the nature of the vaccines, from live attenuated agents to subunits, their efficacy and safety, and the kind of the immune responses generated by those vaccines, which are so effective. To date, all licensed vaccines generate especially specific antibodies, which attach to the infectious agent and therefore can very largely prevent infection. These vaccines have been so effective in developed countries in preventing mortality after a subsequent infection that attempts are being made to develop vaccines against many of the remaining infectious agents. Many of the latter are difficult to manipulate; they can cause persisting infections or show great antigenic variation. A range of new approaches to improve selected immune responses, such as immunization with DNA or chimeric live vectors, viral or bacterial, are under intense scrutiny, as well as genomic analysis of the agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.